This announcement is not an offer to sell, or a solicitation of an offer to acquire any securities. This announcement is not a prospectus and investors should not purchase any securities referred to in this announcement except on the basis of information in the prospectus published by Probiodrug AG  as approved by the competent German regulator Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) on 10 October 2014 and passported to the Dutch Authority for Financial Markets (Autoriteit Financiële Markten) in connection with the Initial Public Offering and admission to trading of its shares on Euronext Amsterdam.

Capital increase from authorized capital in connection with the Greenshoe option has been completed

HALLE/SAALE, Germany, November 14, 2014 - The completion of the capital increase from the authorized capital, which was resolved upon by the management board of Probiodrug AG on 12 November 2014 in connection with the exercise of the Greenshoe option by Kempen & Co, in its capacity as stabilization manager, on the same day, was registered with the commercial register today.

Upon registration of the completion of the capital increase with the commercial register the Company's share capital has been increased from EUR 6,717,102.00 by EUR 48,796.00 to EUR 6,765,898.00 - by issuing 48,796 new shares with no par value and with a notional par value of EUR 1.00 per share (the "New Shares").

The New Shares will be delivered by Kempen & Co to existing shareholders of the Company who lent to Kempen & Co existing shares of the Company in connection with the settlement of the over-allotment. The New Shares will be admitted to trading on Euronext on or around 17 November 2014 and will be subject to the lock-up undertakings of the recipients.

For more information please contact:

Probiodrug AG
Registered at Amtsgericht of Stendal, HRB 213719
Management Board: Dr. Konrad Glund, Dr. Hendrik Liebers
Chairperson of the Supervisory Board: Dr. Erich Platzer

About Probiodrug AG
Headquartered in Halle, Germany, Probiodrug AG (Euronext: PBD) is a biopharmaceutical company focused on the development of new therapeutic products for the treatment of Alzheimer's Disease.

Alzheimer's Disease is a neurological disorder, which is the most common form of dementia. Probiodrug has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's Disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.

These materials are not for distribution, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities. The shares in Probiodrug AG (the "Shares") mentioned herein may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "Securities Act"). The Shares have not been, and will not be, registered under the Securities Act and will not be offered or sold in the United States, except on the basis of applicable exemptions from registration. There will be no public offering of securities in the United States or anywhere outside of The Netherlands. The public offer in The Netherlands was made exclusively by means of and on the basis of an English-language prospectus.